Aclaris Therapeutics’ (ACRS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.75.

Aclaris Therapeutics Stock Performance

ACRS stock opened at $4.50 on Wednesday. The firm has a market cap of $487.58 million, a PE ratio of -3.26 and a beta of 0.41. The firm’s fifty day moving average is $2.99 and its 200 day moving average is $2.28. Aclaris Therapeutics has a one year low of $1.05 and a one year high of $4.89.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.01. Aclaris Therapeutics had a negative net margin of 900.01% and a negative return on equity of 39.73%. The business had revenue of $3.30 million for the quarter, compared to analyst estimates of $1.59 million. Research analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Three Bridge Wealth Advisors LLC purchased a new stake in shares of Aclaris Therapeutics in the third quarter valued at about $1,358,000. Goldman Sachs Group Inc. boosted its holdings in Aclaris Therapeutics by 29.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 555,953 shares of the biotechnology company’s stock valued at $851,000 after purchasing an additional 127,366 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Aclaris Therapeutics by 10.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,433,850 shares of the biotechnology company’s stock valued at $3,453,000 after buying an additional 238,659 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $28,000. Finally, ProShare Advisors LLC acquired a new stake in shares of Aclaris Therapeutics during the 2nd quarter worth approximately $26,000. Hedge funds and other institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical?stage biopharmaceutical company focused on discovering, developing and commercializing novel small?molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non?melanoma skin lesions. Lead programs include ATI?50002, a topical agent in late?stage development for molluscum contagiosum removal; ATI?50003 for common wart resolution; ATI?1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI?450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.